NEW YORK - The United States, which under President Donald Trump has pursued efforts to roll back "diversity, equity and ...
Republican lawmakers have defended the amendment as a straightforward fix. GOP state Rep. Dave Murphy argued it "restores ...
The Wisconsin Assembly — seeking to align state policy with Trump administration initiatives — passed bills Thursday to ...
Huffman’s argument came in response to a June 24 ruling, by Franklin County Common Pleas Judge Jaiza N. Page, that Ohio’s ...
Gilead Sciences GILD recently announced that it has exercised its combined option to exclusively license Assembly Biosciences’ ASMB herpes simplex virus (HSV) helicase-primase inhibitor programs. The ...
Gilead Sciences, Inc. (NASDAQ: GILD) and Assembly Biosciences, Inc. (NASDAQ: ASMB) announced on Monday that Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes ...
(RTTNews) - Gilead Sciences (GILD) and Assembly Biosciences (ASMB) announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus helicase-primase ...
FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus ...
– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback